Acamprosate CalciumThird Party Manufacturing in India

Acamprosate Calcium is a synthetic compound structurally similar to the endogenous amino acid homotaurine, which itself resembles both gamma-aminobutyric acid (GABA) and taurine. While its exact mechanism is not fully characterized, acamprosate is understood to modulate glutamatergic neurotransmission in the central nervous system, particularly at the N-methyl-D-aspartate (NMDA) receptor. Chronic alcohol consumption disrupts the balance between excitatory (glutamatergic) and inhibitory (GABAergic) signaling in the brain, leading to a hyperglutamatergic state during withdrawal that drives cravings and relapse. Acamprosate acts as a functional NMDA receptor antagonist, reducing excessive glutamate activity and restoring the neurochemical equilibrium disrupted by long-term alcohol use. It also acts as a positive allosteric modulator at GABA-A receptors, enhancing inhibitory neurotransmission. By attenuating the glutamatergic hyperactivity characteristic of early abstinence, acamprosate reduces the physiological and psychological urge to drink. Its onset of therapeutic effect is gradual over several days of consistent dosing, and it is not metabolized by the liver, making it suitable for patients with hepatic impairment. The drug is absorbed slowly from the gastrointestinal tract with a bioavailability of approximately 11% and is primarily excreted unchanged by the kidneys.

Therapeutic Uses

Acamprosate Calcium is prescribed for the treatment of:

• Alcohol dependence (maintenance of abstinence): First-line pharmacotherapy for maintaining abstinence in alcohol-dependent patients who have completed detoxification and are in the early stages of recovery.
• Craving reduction: Specifically indicated for reducing the psychological craving for alcohol that often precedes relapse, helping patients resist the urge to drink.
• Relapse prevention: Clinical evidence supports its use in combination with psychosocial support and counseling programs for sustained abstinence.

Why Manufacturers Choose Acamprosate Calcium

Acamprosate Calcium occupies a unique niche among neurological/psychiatric molecules as one of only three FDA-approved pharmacotherapies for alcohol dependence (alongside disulfiram and naltrexone). With rising global awareness of alcohol use disorder as a treatable medical condition — and increasing destigmatization of addiction treatment — the demand for acamprosate is growing steadily across both developed and emerging markets. Indian manufacturers produce acamprosate as 333mg gastro-resistant (enteric-coated) tablets, which protect the drug from gastric acid and ensure reliable delivery to the small intestine for absorption. The gastro-resistant formulation requires specialized coating capabilities, making it a value-added product for manufacturers with enteric coating expertise. This product is well-suited for PCD franchise distribution in India and for export to countries where alcohol dependence treatment programs are expanding. Acamprosate Calcium is one of the specialized molecules for third party manufacturing in India, catering to the growing neuropsychiatry segment with consistent institutional and hospital demand.

Dosage Forms

• Gastro Resistant Tablet: 333mg (enteric-coated)